Reuters
10 Jul 2026, 11:38 UTC · 2h ago
GSK's targeted cancer therapy shows positive results in late-stage study
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
10 Jul 2026, 11:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
GSK's experimental drug for advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial. — Positive late-stage (Phase 3) data significantly increases the probability of regulatory approval and future commercial revenue.
+0.60Which stocks this story touches
Experimental drug for lung cancer showed positive results in a late-stage trial.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Market Watch
2h ago
